tbuckley/cabot-search huggingface dataset:
AB0347 CLINICAL RELEVANCE OF ANTI-CARBAMYLATED PROTEIN ANTIBODY: IS IT SAME AS CAUCASIANS IN ASIANS?
Authors: Jung Yoon Pyo, Seungmin Jung, Sangwon Lee, Jason Jungsik Song, Yongbeom Park
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Recently, there was an interesting study demonstrating that anti-CarP was associated with more inflammation and higher baseline disease activity in French ESPOIR cohort [1]. However, all of the investigated patient cohorts have been Caucasian. However, considering the genes associated with RA are different in Caucasians and Asians, PTPN22 in Caucasians and PADI4 in Asians, and those genes contribute to the loss of tolerance and autoantibody production, clinical relevance of anti-CarP might be different in Asians. <h3>Objectives</h3> Therefore, we investigated the clinical significance of anti-CarP in Korean patients with early RA focused on initial presentations and treatment outcome. <h3>Methods</h3> The anti-CarP antibodies were analysed by commercial ELISA (Novateinbio, USA) in the Korean Intensive Management of Early Rheumatoid Arthritis cohort. All patients were DMARD-naïve RA patients with symptom duration less than 1 year. They were intensively treated by adjusting medications every 4 weeks, and treated to target as disease activity score (DAS)28 of &lt; 2.6. Baseline clinical characteristics and disease outcomes were compared according to the presence of anti-CarP antibodies. <h3>Results</h3> A total of 128 patients were included, 67 patients (52.3%) were positive for anti-CarP antibody at presentation. After 2 years of treatment, proportion of anti-CarP positivity decreased to 38.1% (p=0.049), but titration did not change (6.87 to 4.45 ng/ml, p=0.074). Patients without anti-CarP antibody presented with more tender joint count (TJC) (7.3 vs. 5.2, p=0.055), swollen joint count (SJC) (4.1 vs. 2.6, p=0.019) and higher baseline physician global VAS (5.5 vs 4.7, p=0.005) than patients with anti-CarP antibody. Subgroup analysis with ACPA negative patients, patients without anti-CarP antibody showed more TJC (13.7 vs. 4.7, p=0.043), SJC (7.9 vs. 3.0, p=0.076), higher patient global VAS (5.9 vs. 3.7, p=0.044) and DAS28-ESR (6.1 vs. 4.7, p=0.051). After intensive treatment, there were no differences in remission rate and DAS28-ESR at 12, 24, and 36 months. <h3>Conclusion</h3> Interestingly, RA patients without anti-CarP antibody presented with more TJC/SJC than those with anti-CarP antibody in Korean patients. This finding is contrast to previous studies which were done with Caucasians. Further investigation is needed to conclude the clinical implications of anti-CarP. <h3>References</h3> [1] Truchetet ME, Dublanc S, Barnetche T, Vittecoq O, Mariette X, Richez C, et al. Association of the Presence of Anti-Carbamylated Protein Antibodies in Early Arthritis With a Poorer Clinical and Radiologic Outcome: Data From the French ESPOIR Cohort. Arthritis Rheumatol 2017;69(12):2292-302. <h3>Disclosure of Interests</h3> None declared
Identification of cis-regulatory mutations generating de novo edges in personalized cancer gene regulatory networks
Authors: Zeynep Kalender Atak, Hana Imrichova, Dmitry Svetlichnyy, Gert Hulselmans, Valerie Christiaens, Joke Reumers, Hugo Ceulemans, Stein Aerts
Journal: Genome Medicine (2017)

The identification of functional non-coding mutations is a key challenge in the field of genomics. Here we introduce μ-cisTarget to filter, annotate and prioritize cis-regulatory mutations based on their putative effect on the underlying "personal" gene regulatory network. We validated μ-cisTarget by re-analyzing the TAL1 and LMO1 enhancer mutations in T-ALL, and the TERT promoter mutation in melanoma. Next, we re-sequenced the full genomes of ten cancer cell lines and used matched transcriptome data and motif discovery to identify master regulators with de novo binding sites that result in the up-regulation of nearby oncogenic drivers. μ-cisTarget is available from http://mucistarget.aertslab.org .
AB1189 THE IMPORTANCE OF POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY (PET -CT) IN FEVER OF UNKNOWN ORIGIN (FUO) AND INFLAMMATION OF UNKNOWN ORIGIN (IUO)
Authors: Tahir Saygın öğüt, Veli yazısız, Funda Erbasan, Mustafa Ender Terzioğlu
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Fever of unknown origin (FUO) and inflammation of unknown origin (IUO) are rare clinical problems but diagnostically challenging for clinicians. Patients are exposed to extensive and expensive medical examinations for the identification of the FUO/IUO. FDG PET-CT can help to identify the underlying disease in these patients. <h3>Objectives</h3> The aim of this study was to evaluate the role of PET-CT in patients with FUO/IUO and to identfy FDG uptake sites and patterns <h3>Methods</h3> Total of 286 patients who were performed 18F FDG-PET-CT between Jan 2014 and Dec 2017 were evaluated, retrospectively. There were a total 62 patients scanned by PET-CT for FUO/IUO. Definitive diagnosis, PET-CT patterns, organ involvement and SUVmax values in these patients were reevaluated <h3>Results</h3> Rheumatic disease in 27 patients (43.5%), 20 malignancy (32.3%) and 6 infectious diseases (9.7%) were diagnosed in the FUO/IUO patients performed PET-CT scan. Systemic vasculitis were the most frequently diagnosed rheumatic disease. 11 patients of the 62 patients (17.7%) were diagnosed large vessel vasculitis (9 Takayasu arteritis, 2 Temporal arteritis). Significant vascular FDG involvement was detected (77.7%) in these patients. 4 of 7 patients diagnosed Takayasu arteritis were not seen any pathological finding in the other imaging modalities. Vascular FDG uptake (p &lt; 0.001) was statistical significantly higher in the patients diagnosed with rheumatic disease whereas lymph node (p = 0.013) and bone (p = 0.005) FDG uptake were significantly higher in patients with malignancy. Patients with malignancy had the highest SUVmax mean value (p &lt; 0.001). <h3>Conclusion</h3> Our findings reveal that PET-CT is a useful imaging modality in the FUO/IUO patients. Inflammatory diseases, especially large vessel vasculitis, should be considered in addition to malignancies in these patients, and subclinical inflammation in the blood vessel can be visualised by PET -CT <h3> Disclosure of Interests</h3> None declared
Abstract 14225: Evidence of Subclinical Left Ventricular Dysfunction in Pericarditis
Authors: Jordan Long, Selena Chandler, Samuel Kulifay, Ellianna Hoff, Rohith Raghavendran, J. Ronald Mikolich
Journal: Circulation (2018)

Background: Abnormalities of LV strain have been shown to occur prior to impairment of global left ventricular function, measured by global LV ejection fraction (EF). Although initially described i...
Abstract 354: Sirt1 Negatively Regulates Cardiac Inflammation Induced by Metabolic Stress
Authors: Kevin Schesing, Junichi Sadoshima, Shinichi Oka
Journal: Circulation Research (2015)

Obesity is a major risk factor for heart disease. Metaflammation is a metabolically driven, chronic, low-grade inflammatory reaction that is seen in the heart under obese conditions. Cardiac myocytes are known to produce inflammatory cytokines such as interleukin-6 (IL-6). However, whether and how cardiac myocytes mediate metaflammation is unknown. Silent information regulator 1 (Sirt1), a histone deacetylase involved in numerous metabolic pathways, facilitates an anti-inflammatory function through inhibition and deacetylation of the NFkB p65 subunit. This project aims to examine whether Sirt1 plays a role in cardiac local metaflammation. Mice with cardiac specific Sirt1 gene deletion (c-Sirt1 KO), Sirt1 overexpression (Tg-Sirt1), and relevant controls (Flox/Flox and WT respectively) were each placed on high fat and regular chow diets. The mice were euthanized after 3 months and their hearts were extracted for genetic and molecular analyses. Sirt1 mRNA and protein levels were significantly decreased under HFD feeding conditions (50% reduction in HFD feeding compared to normal diet, P&lt;0.05). Acetylation of p65 was significantly induced by HFD feeding, and was further enhanced in c-Sirt1 KO mice, but inhibited in Tg-Sirt1 mice. Cardiac inflammation was enhanced in the c-Sirt1 KO group as evidenced by a significant increase in mRNA levels of IL-6 in mice fed regular chow (3-fold increase in c-Sirt1 KO vs. Sirt1 Flox/Flox, p&lt;0.05) and HFD (5-fold increase in c-Sirt1 KO vs. Sirt1 Flox/Flox, p&lt;0.05). Intracellular IL-6 signaling steps, such as phosphorylation of STAT3, were enhanced in c-Sirt1 KO, but inhibited in Tg-Sirt1 mice under HFD feeding conditions. These results suggest that cardiac myocytes mediate metaflammation partly through downregulation of Sirt1.
Disparities in Prevalence and Treatment of Mental Health Disorders in Children
Authors: Ruiyi Gao, Andrew Adesman
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Abstract 12806: Advanced Airway Management May Not be Effective Compared to Basic Airway Management After Pediatric Out-of-hospital Cardiac Arrest
Authors: Tatsuma Fukuda, Naoko Ohashi-Fukuda, Naoki Hayase, Tomoki Wada, Takehiro Matsubara, Kent Doi, Naoki Yahagi
Journal: Circulation (2016)

Introduction: Respiratory care for pediatric out-of-hospital cardiac arrest (OHCA) may play an important role due to the asphyxial nature of the majority of pediatric OHCA events. Hypothesis: We assessed the hypothesis that prehospital advanced airway management (endotracheal intubation or supraglottic airway device) is associated with an increased chance of favorable outcomes compared with basic airway management (bag-valve-mask ventilation) after pediatric OHCA. Methods: This was a nationwide, population-based, propensity score-matched study of pediatric OHCA in Japan from January 1, 2011, to December 31, 2012, based on data from the All-Japan Utstein Registry. We included pediatric patients aged &lt; 18 years. Infants (≤ 1 year old) were excluded. The primary outcome was a favorable neurological state one month after OHCA defined as a Glasgow-Pittsburgh cerebral performance category (CPC) score of 1-2 (corresponding to a Pediatric CPC score of 1-3). The secondary outcomes included a neurologically favorable survival with a CPC score of 1 (corresponding to a Pediatric CPC score of 1), one-month survival, and prehospital return of spontaneous circulation (ROSC). Results: A total of 2,157 patients were included in the final cohort; 365 received advanced airway management and 1,792 received basic airway management. Among 2,157 patients, 213 (9.9%) survived with a favorable neurological status one month after OHCA. There were no significant differences in neurologically favorable survival between the advanced airway management group and the basic airway management group after adjusting for potential confounders: propensity score matching, OR 0.74 (95%CI 0.35-1.59), and multivariable logistic regression modeling, OR 0.55 (95% CI 0.24-1.14). Similar findings were observed for the secondary outcomes. In subgroup analyses (including the non-cardiac [mainly asphyxial] etiology group), there were no subgroups in which advanced airway management was associated with neurologically favorable survival. Conclusions: In conclusion, advanced airway management was not associated with an increased chance of neurologically favorable survival, one-month survival, or prehospital ROSC compared to basic airway management after pediatric OHCA.
PB1688 SUCCESSFUL HAPLOIDENTIC BONE MARROW TRANSPLANTATION WITH INOTUZUMAB OZOGAMICIN IN PATIENT WITH RELAPSED AND RESISTANT B CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Authors: A. Ünal, S. Çelik, Z. T. Güven, B. Eser, L. Kaynar, M. Çetin
Journal: HemaSphere (2019)

Background: Although chemotherapeutic(CT) agents that used in the treatment of acute lymphoblastic leukemia(ALL) increase survival, the results are still weak. Long‐term survival with CT's in relapse ALL cases is difficult and the prognosis is very weak. Inotuzumab ozogamicin is an anti‐CD 22 monoclonal antibody and it has the potential to reduce the overall toxicity of intensive regimens for ALL, as well as to possibly increase the number of patients who may achieve a state of minimal residual disease. Aims: We aimed to present a case of successful haploidentic bone marrow transplantation in a recurrent B‐ALL patient who was in remission with inotuzumab ozogamicin. Methods: Case description: 26‐year‐old male patient was diagnosed with B‐cell ALL in December 2017. After the HOELZER CT protocol was started, maintenance treatment was continued.In the fifth month of treatment,FLAG CT protocol was started cause of recurrence was seen on 5% blast detection in peripheral blood smear. In August 2018, inotuzumab ozogamicin treatment was started and six cures were completed because the patient was not in remission. In September 2018, He had gone Haploidentical bone marrow transplantation from his sibling donor(8/10) with Defibrotid prophylaxis for Veno‐Occlusive Disease(VOD)s. He engrafted succesfully and chimerizm was 99.85% in 30th days of transplantation. He is 60th day of transplantation and in a remission. Results: Bone marrow transplantation cannot be performed since the complete response cannot be achieved in patients with relapse and resistant B‐ALL. In these patients, new therapies targeting malignant lymphoblasts are needed. Inotuzumab ozogamicinis a monoclonal antibody drug conjugate that targets CD22 antigen on malignant lymphoblasts.In many studies, it has been shown that Inotuzumab ozogamycin is effective and reliable anti‐tumor activity in adults with recurrent and resistant CD22 positive ALL. However, monoclonal antibody drug conjugates have been shown to be associated with VOD's. For this purpose, we used Defibrotid to protect our patient from VOD. Summary/Conclusion: Treatment with combination CT regimens in B‐ALL is suboptimal and long‐term survival is achieved in only 30‐40% of patients. Targeted molecular therapy and new regimens are needed in relapse and resistant patients. At this point, Inotuzumab ozogamycin is an anti‐CD‐22 monoclonal antibody, as in our case, it provides remission in recurrent and resistant B‐ALL patients and allows patients to complete their treatment with an allogeneic transplant from a fully compatible donor.
THU0378 COEXISTENCE OF ANKYLOSING SPONDYLITIS AND RHEUMATOID ARTHRITIS (ANALYSIS OF 73 CASES)
Authors: Bryan-Josué Flores Robles, Valvanera Pinillos, Angel Elena-Ibáñez, Eztizen Labrador-Sánchez, Leticia Merino-Meléndez, Juan Antonio López-Martín, Enrique Ramalle-Gómara
Journal: Annals of the Rheumatic Diseases (2019)

seen after adjustments.There were no significant associations between dactylitis or enthesitis and either IHD or stroke (Table ).Abstract THU0377 -Table 1 Model 1 adjusted for age and sex Model 2 adjusted for age, sex and BMI
In situ microwave tumor coagulation plus cytokine-microparticles induced potent antitumor immunity
Authors: Tadao Ohno, Ming Kuang, Shuqin Liu, Kaoru Saijo, Eiji Uchimura, Lan Huang, Kam W. Leong, Jie F. Huang
Journal: Cancer Research (2004)

665  Introduction: Antitumor immunity has the potential to control residual or metastatic disease following removal of a primary tumor. We evaluated the antitumor efficacy of in situ tumor vaccines in a minimal residual disease. Materials and Methods: We used local microwave coagulation and subsequent intratumoral injection of biodegradable microparticles encapsulating interleukin-2 and granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat subcutaneous tumors in syngeneic mice. Results: The in situ treatment eradicated the original tumors and elicited a potent systemic antitumor immunity that both protected treated mice from re-challenge with the same tumor cells and rejected the distal tumors in a bilateral tumor model. The combination of local-hyperthermia and immunotherapy was much more effective in suppressing tumor growth and improving survival than either treatment alone. In addition, a cytotoxicity assay indicated that both T-cells and natural killer cells acted as the effector cells in the induced antitumor immunity. Conclusions: These data highlight the feasibility of using an in situ cancer vaccination in combination with local tumor coagulation as a clinical therapy. (Partly supported by Ministry of Education, Culture and Technology of Japan).
AB1354-HPR DESCRIPTION OF INDIVIDUALS WITH FIBROMYALGIA SYNDROME
Authors: Berna Cagla Caglayan, Elif Gur Kabul, Aylin Keskin, Bilge Basakci Calik, Ugur Karasu
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Fibromyalgia (FM) affects negatively physical and mental health and reduces quality of life. The most common symptom is chronic widespread musculoskeletal pain in FMS. <h3>Objectives</h3> This study was planned to investigate comorbidities, number of medication and to determine the most painful body region in individuals with FM. <h3>Methods</h3> The study included 166 individuals (161 women, 5 men) who were diagnosed with FM, with a mean age of 47.5610.91 years. Comorbidities, number of medication which were used for FMS or other diseases of participants were recorded also painful body regions were assessed for 28 regions. The categorical variables were expressed in numbers and percentage. <h3>Results</h3> The results showed that a total of 42.8% (n=71) of individuals in this study had no comorbidities, 11.4% (n=19) of individuals had hypertension and 7.8% (n=13) of individuals had asthma. When the number of medication were examined, a total of 66.3% (n=110) of individuals did not use any medication, 25.8% (n=43) of individuals did use one type of medication with FM-related and 4.2% (n=7) of individuals did use two type of medications with FMSrelated. Painful body regions were reported by 74.1% (n=123) for neck, 66.3% (n=110) right shoulder, 68.7% (n=114) left shoulder,68.1% (n=113) right knee and 68.1% (n=113) left knee. <h3>Conclusion</h3> In general, there was no comorbidities with FMS. The study found that individuals with FMS usually did not use medication. Also neck were found the most painful body region in individuals with FMS. <h3>References</h3> [1] Clauw DJ. Fibromyalgia: An overview. Am J Med 2009; 122(12 Suppl):S3-S13 [2] Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, et al. The Am College of Rheumatol 1990 criteria for the classification of Fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum. 1990; 33:160-72. <h3>Disclosure of Interests</h3> None declared
Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis
Authors: Thomas Bieber
Journal: Allergy (2019)

Abstract Atopic dermatitis (AD) is a common inflammatory skin condition that has traditionally been considered a paradigmatic type 2 immunity (T2)‐driven disease. Interleukin (IL)‐4 and IL‐13 are both pivotal cytokines involved in the generation of allergic diseases. Currently, besides dupilumab, which blocks the binding of both cytokines to their receptors, a number of new pharmacologic entities have been designed to target both T2 cytokines and/or their receptors and/or receptor‐associated signal transduction machinery such as Janus kinases. Recently, IL‐13 has been suggested to be the key T2 cytokine driving inflammation in the periphery, while IL‐4 may merely have a central effect. There is increasing evidence that this concept holds true for the inflammatory reaction underlying AD, where IL‐13 is overexpressed locally and has a significant impact on skin biology, including the recruitment of inflammatory cells, the alteration of the skin microbiome, and the decrease in the epidermal barrier function. This review provides an update on the role of IL‐13 in AD and discusses the different strategies aimed at interfering with its biologic activity as well as their potential in a precision medicine approach in the management of AD.
AB0419 FRACTURE RISK IN PATIENTS ON LONG TERM GLUCOCORTICOIDS WITH INFLAMMATORY ARTHRITIS
Authors: Jemma Buchalter, Ahmed Elmahdi, Aine Gorman, Qutab Shah, Angela Camon, Ausaf Mohammad, Killian O’rourke
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> A main stay treatment of inflammatory arthritis is glucocorticoids (GCs)<sup>[1]</sup>. However, long term use of GCs has been associated with an increased risk of fracture, with studies estimating up to 12% of patients having sustained a fracture whilst on GC treatment<sup>[1][2]</sup>. <h3>Objectives:</h3> The aim of this study was to determine the prevalence of fractures in a cohort of patients on long term GCs with a diagnosis of inflammatory arthritis. <h3>Methods:</h3> A database of patients with inflammatory arthritis attending the rheumatology department at the Midlands Regional Hospital Tullamore, since 2009, was reviewed. Patients on long term GCs were identified and outpatient summaries were analysed. Data collection included age, sex, diagnosis, vertebral fracture, other fracture sites and osteoporosis treatment. <h3>Results:</h3> As of September 2018, out of the 2118 patients with a diagnosis of inflammatory arthritis 364 were on long term GCs. 10% of patients had reported vertebral fractures on imaging. 36.4% of patients had other types of fractures reported on imaging; 20%, and the most common site of fracture, were wrist fractures. 83.7% of those who suffered from a vertebral fracture were female. 18.2% of those who sustained fractures were not on any osteoporosis treatment. <h3>Conclusion:</h3> The incidence of fracture in our cohort of patients was higher than suggested in previous studies. Furthermore, it highlights the need for patients on long term GCs to be given osteoporosis prevention therapy. <h3>References</h3> [1] Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017;69:1521–37 [2] Dam Kim, Soo-Kyung Cho, Byeongju Park, Eun Jin Jang, Sang-Cheol Bae and Yoon-Kyoung Sung. The Journal of Rheumatology March 2018, jrheum.170054 <h3>Disclosure of Interests:</h3> None declared
Abstract 13799: Comparing Incidence of Stroke and Non-CNS Embolism in Patients With Symptomatic and Asymptomatic Atrial Fibrillation: Insights From the ORBIT AF Registry
Authors: Munveer Thind, DaJuanicia Holmes, Marwan Badri, Karen Pieper, Amitoj Singh, Rosalia Blanco, Gregg C Fonarow, Bernard J Gersh, Kenneth W Mahaffrey, Eric D Peterson, Jonathan P Piccini, Peter R Kowey
Journal: Circulation (2017)

Introduction: Management of asymptomatic patients with atrial fibrillation (AF) is controversial, in part because the risk of thromboembolism (TE) has not been well described. This study aims to co...